Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Newly approved breast cancer treatment not possible on NHS

The chief executive of health watchdog Nice told ITV News he is “disappointed” that drug manufacturer Roche has not offered the NHS a discount on a breast cancer drug that costs around £90,000 per patient.

The chief executive of health watchdog Nice told ITV News he is “disappointed” that drug manufacturer Roche has not offered the NHS a discount on a breast cancer drug that costs around £90,000 per patient. Kadcyla, which extends women’s lives by almost six months, could be blocked from routine NHS access because it is too expensive. “Companies can discount their prices and they frequently do. Given the list price. I would have expected the company to have at least considered (a discount),” Andrew Dillon said.  For more information visit ITV.

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy